IP Library Granted Patent US 7,116,688
Granted Patent B2
US 7,116,688 · App. 10/635,154 · Granted Oct 3, 2006

Laser system and method for generation of a pulse sequence with controllable parameters and computer program product

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,116,688
App. No.
10/635,154
Granted
Oct 3, 2006
Kind
B2
Abstract

A laser system for generating at least one pulse and/or pulse sequence(s) of pulses having at least one specified property, such as pulse energy, duration, peak intensity, pulse form and/or timing includes an amplifying cavity. The amplification process is monitored in the amplifying cavity to obtain data about at least one property of the pulse sequence and/or the single pulse(s). The system also compares the obtained data with reference data and it controls at least one switching means for inputting, outputting and/or retaining the pulse(s) in the amplifying cavity such that at least one property of the pulse sequences and/or the pulses at an output of the laser system has substantially a specified value.

Claims (33)

1. A laser system for generating an amplified laser pulse having at least one specified pulse property, said system comprising:

an optical pulse source for generating a seed pulse;

an amplifying cavity;

a switching means for introducing the seed pulse into said amplifying cavity at a predetermined entry time; and

a detecting means for monitoring amplification of the seed pulse in the amplifying cavity, and for sending data to a control means, wherein said control means determines when the seed pulse has been amplified to have a prescribed value of the specified pulse property, and wherein said switching means is responsive to said control means, for outputting the amplified pulse having the specified pulse property from the amplifying cavity at a predetermined emission time.

2. A system as recited in claim 1 wherein the entry time (T K-1 ) of the seed pulse, and the emission time of the amplified pulse (T K ) have a relationship of T K =ΔT k +T K-1 , wherein ΔT K is determined by said control means.

3. A system as recited in claim 1 wherein the energy of the seed pulse at entry time (E K-1 ), and the energy of the amplified pulse at emission time (E K ) have a relationship of E K =ΔE K +E K-1 , wherein ΔE K is determined by said control means.

4. A system as recited in claim 1 wherein the duration of the seed pulse at entry time (τ K-1 ), and the duration of the amplified puke at emission time (τ K ) have a relationship of τ K =Δτ K +τ K-1 , wherein Δτ K is determined by said control means.

5. A system as recited in claim 4 wherein pulse duration is substantially constant (Δτ K =o).

6. A system recited in claim 1 wherein said control means compares data from said detecting means with reference data to determine when a prescribed value of the specified pulse property determined from an external application is obtained.

7. A system as recited in claim 6 wherein the reference data includes pulse property information selected from the group of pulse properties consisting of pulse energy, pulse duration, peak intensity, pulse form, time and combinations thereof.

8. A laser system as recited in claim 1 wherein the seed pulse is part of a pulse sequence and the system further comprises at least one pulse dispersion compensating means for compensating the dispersion of the seed pulse per amplifying cavity pass such that the duration of the pulses in the pulse sequence at an output of the laser system is substantially constant.

9. A laser system as recited in claim 1 further comprising at least one pulse dispersive means for introducing a specified amount of pulse dispersion per amplifying cavity pass so that the pulse duration at an output of the laser system is variable.

10. A laser system as recited in claim 1 further comprising at least one pulse dispersive means for introducing an amount of pulse dispersion per amplifying cavity pass such that the peak intensity of the pulses in the amplifying cavity is less than a predetermined value.

11. A laser system as recited in claim 1 further comprising at least one pulse dispersive means for generating spatially divided pulse spectral components in the amplifying cavity such that at least one pulse spectral component is selectively amplified to increase the effective amplification bandwidth of the laser system.

12. A method for generating an amplified laser pulse having at least one specified pulse property, said method comprising the steps of:

generating a seed pulse;

introducing the seed pulse into an amplifying cavity using a switching means at a predetermined entry time;

monitoring amplification of the seed pulse in the amplifying cavity to determine when the seed pulse has been amplified to have a prescribed value of the specified pulse property; and

outputting the amplified pulse having the specified pulse property from the amplifying cavity at a predetermined emission time.

13. A method as recited in claim 12 wherein the entry time (T K-1 ) of the seed pulse, and the emission time of the amplified pulse (T K ) have a relationship of T K =ΔT K +T K-1 , and wherein ΔT K is predetermined.

14. A method as recited in claim 12 wherein the energy of the seed pulse at entry time (E K-1 ), and the energy of the amplified pulse at emission time (E K ) have a relationship of E K =ΔE K +E K-1 , and wherein ΔE K is predetermined.

15. A method as recited in claim 12 wherein the duration of the seed pulse at entry time (τ K-1 ), and the duration of the amplified pulse at emission time (τ K ) have a relationship of τ K =Δτ K +τ K-1 , and wherein Δτ K is predetermined.

16. A method as recited in claim 15 wherein pulse duration is substantially constant (Δτ K =o).

17. A method as recited in claim 12 further comprising the step of comparing data during amplification of the seed pulse with selected reference data to determine when the prescribed value of the specified pulse property is obtained.

18. A method as recited in claim 17 wherein the reference data includes pulse property information selected from the group of pulse properties consisting of pulse energy, pulse duration, peak intensity, pulse form, time and combinations thereof.

19. A laser system for generating an amplified laser pulse having at least one specified pulse property, said system comprising:

an optical pulse source for generating a seed pulse;

an amplifying cavity;

a first switching means for introducing the seed pulse into said amplifying cavity at a predetermined entry time;

a detecting means for monitoring amplification of the seed pulse in the amplifying cavity, and for sending data to a control means, wherein said control means determines when the seed pulse has been amplified to have a prescribed value of the specified pulse property; and

a second switching means, responsive to said control means, for outputting the amplified pulse having the specified pulse property from the amplifying cavity at a predetermined emission time.

20. A laser system as recited in claim 19 further comprising at least one passive switching means, whose state does not depend on the control means.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023065/0970 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023065/0012 →
CHANGE OF NAME Recorded Aug 5, 2009
From: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
To: 20/10 PERFECT VISION AG
Reel/Frame 023056/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2003
From: SAUTER, THOMAS; ZICKLER, LEANDER
To: UNIVERSITY OF HEIDELBERG; 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
Reel/Frame 014736/0226 →